Literature DB >> 17928883

Serglycin proteoglycan in hematologic malignancies: a marker of acute myeloid leukemia.

C U Niemann1, L Kjeldsen, E Ralfkiaer, M K Jensen, N Borregaard.   

Abstract

Serglycin is the major cell-associated proteoglycan of hematopoietic cells. Previous work has demonstrated that serglycin may be involved in targeting some proteins to granules of cytotoxic lymphocytes, mast cells and neutrophils. We characterized the expression of serglycin in various hematologic malignancies by immunohistochemistry and ELISA. Serglycin expression was found to distinguish acute myeloid leukemia (AML) from acute lymphoblastic leukemia. In contrast to myeloperoxidase, serglycin was found to be a selective marker for immature myeloid cells, distinguishing AML from Philadelphia chromosome-negative chronic myeloproliferative disorders.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17928883     DOI： 10.1038/sj.leu.2404975

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


  22 in total

Review 1.  When Glycosylation Meets Blood Cells: A Glance of the Aberrant Glycosylation in Hematological Malignancies.

Authors:  Huining Su; Mimi Wang; Xingchen Pang; Feng Guan; Xiang Li; Ying Cheng
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

2.  Serglycin is a major proteoglycan in polarized human endothelial cells and is implicated in the secretion of the chemokine GROalpha/CXCL1.

Authors:  Astri J Meen; Inger Øynebråten; Trine M Reine; Annette Duelli; Katja Svennevig; Gunnar Pejler; Trond Jenssen; Svein O Kolset
Journal:  J Biol Chem       Date:  2010-11-12       Impact factor: 5.157

3.  Serglycin (SRGN) overexpression predicts poor prognosis in hepatocellular carcinoma patients.

Authors:  Lu He; Xinke Zhou; Chen Qu; Yunqiang Tang; Qiong Zhang; Jian Hong
Journal:  Med Oncol       Date:  2013-08-31       Impact factor: 3.064

4.  Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization.

Authors:  Anurag Purushothaman; Bryan P Toole
Journal:  J Biol Chem       Date:  2014-01-08       Impact factor: 5.157

Review 5.  Proteoglycans in prostate cancer.

Authors:  Iris J Edwards
Journal:  Nat Rev Urol       Date:  2012-02-21       Impact factor: 14.432

Review 6.  Antithetic roles of proteoglycans in cancer.

Authors:  Elena Garusi; Silvia Rossi; Roberto Perris
Journal:  Cell Mol Life Sci       Date:  2011-10-02       Impact factor: 9.261

Review 7.  The extracellular matrix of hematopoietic stem cell niches.

Authors:  Cornelia Lee-Thedieck; Peter Schertl; Gerd Klein
Journal:  Adv Drug Deliv Rev       Date:  2021-11-25       Impact factor: 15.470

8.  The proteoglycan repertoire of lymphoid cells.

Authors:  Bodil Fadnes; Anne Husebekk; Gunbjørg Svineng; Øystein Rekdal; Masaki Yanagishita; Svein O Kolset; Lars Uhlin-Hansen
Journal:  Glycoconj J       Date:  2012-07-10       Impact factor: 2.916

9.  Expression of distinct RNAs from 3' untranslated regions.

Authors:  Tim R Mercer; Dagmar Wilhelm; Marcel E Dinger; Giulia Soldà; Darren J Korbie; Evgeny A Glazov; Vy Truong; Maren Schwenke; Cas Simons; Klaus I Matthaei; Robert Saint; Peter Koopman; John S Mattick
Journal:  Nucleic Acids Res       Date:  2010-11-12       Impact factor: 16.971

10.  Serglycin is implicated in the promotion of aggressive phenotype of breast cancer cells.

Authors:  Angeliki Korpetinou; Spyros S Skandalis; Aristidis Moustakas; Kaisa E Happonen; Heidi Tveit; Kristian Prydz; Vassiliki T Labropoulou; Efstathia Giannopoulou; Haralambos P Kalofonos; Anna M Blom; Nikos K Karamanos; Achilleas D Theocharis
Journal:  PLoS One       Date:  2013-10-31       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.